NorthCrest Asset Manangement’s Edwards Lifesciences EW Stock Holding History

NorthCrest Asset Manangement’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Buy	3,915 +728	+23%	+$61K	0.01%	672
2026 Q1	$258K	Sell	3,187 -4,002	-56%	-$330K	0.01%	664
2025 Q4	$605K	Buy	7,189 +458	+7%	+$37.6K	0.01%	491
2025 Q3	$516K	Buy	6,731 +2,439	+57%	+$191K	0.01%	484
2025 Q2	$330K	Buy	+4,292	New	+$320K	0.01%	498
2025 Q1	–	Sell	-2,870	Closed	-$212K	–	602
2024 Q4	$212K	Buy	+2,870	New	+$201K	0.01%	538
2024 Q3	–	Sell	-2,212	Closed	-$204K	–	555
2024 Q2	$204K	Hold	2,212	–	–	0.01%	493
2024 Q1	$211K	Buy	+2,212	New	+$186K	0.01%	489
2023 Q3	–	Sell	-2,498	Closed	-$236K	–	507
2023 Q2	$236K	Buy	2,498 +7	+0.3%	+$608	0.01%	472
2023 Q1	$206K	Buy	+2,491	New	+$196K	0.01%	474
2022 Q3	–	Sell	-2,250	Closed	-$214K	–	433
2022 Q2	$214K	Buy	+2,250	New	+$233K	0.01%	415
2022 Q1	–	Sell	-2,250	Closed	-$291K	–	425
2021 Q4	$291K	Buy	+2,250	New	+$262K	0.02%	365

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

NorthCrest Asset Manangement's EW Position: Q2 2026 in Review

NorthCrest Asset Manangement increased its Edwards Lifesciences (EW) stake by 23% in Q2 2026, buying an estimated $61K and bringing the position to 3,915 shares worth $358K. The position accounts for 0.01% of the portfolio, ranked #672.

NorthCrest Asset Manangement first reported a position in EW in Q4 2021 and has held it in 12 quarters since. The position peaked at $605K in Q4 2025. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

NorthCrest Asset Manangement held 3,915 shares of Edwards Lifesciences worth $358K as of Q2 2026.
NorthCrest Asset Manangement bought 728 Edwards Lifesciences shares in Q2 2026, an estimated $61K.
Edwards Lifesciences made up 0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #672 holding.
NorthCrest Asset Manangement first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 12 quarters since.
NorthCrest Asset Manangement's Edwards Lifesciences position peaked at $605K in Q4 2025.
774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.